Protein kinase inhibitor

China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

Wednesday, March 31, 2021 - 9:57am

NMPAs approval of QINLOCK establishes a new standard of care for treating patients with fourth-line GIST in China.

Key Points: 
  • NMPAs approval of QINLOCK establishes a new standard of care for treating patients with fourth-line GIST in China.
  • QINLOCK may potentially alter the treatment landscape for patients in China with GIST.
  • In March 2021, the NMPA approved QINLOCK for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

LOU-064: An Agammaglobulinaemia Tyrosine Kinase Inhibitors Being Developed by Novartis for Sjogren's Syndrome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Thursday, March 25, 2021 - 10:32am

"LOU-064 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's Syndrome in 7 Major Markets.

Key Points: 
  • "LOU-064 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's Syndrome in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • LOU-064 acts as Agammaglobulinaemia tyrosine kinase inhibitors and is being developed by Novartis for Sjogren's syndrome which is currently in Phase II of clinical trial study.
  • Other emerging products for Sjogren's Syndrome are giving market competition to LOU-064 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer

Tuesday, March 23, 2021 - 11:00am

CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.
  • "Chris is a dedicated physician and drug developer who has guided the early development, global registration studies, and marketing approval of multiple kinase inhibitor therapies for patients with cancer," said James Porter, Ph.D., Chief Executive Officer of Nuvalent.
  • "I am delighted to welcome him to the Nuvalent team, where his clinical vision and proven leadership will help drive the progression of our robust pipeline through multiple near-term clinical milestones."
  • Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

Friday, March 12, 2021 - 2:08am

TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).

Key Points: 
  • TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).
  • In this study, LENVIMA plus KEYTRUDA met its dual primary endpoints, overall survival (OS) and progression-free survival (PFS), as well as its secondary efficacy endpoint of objective response rate (ORR).
  • Currently, Eisai is preparing to submit an application for additional indications based on these results in various countries around the world including Japan.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover innovative new medicines with the potential to cure cancer.

Branebrutinib: A Agammaglobulinaemia Tyrosine Kinase Inhibitors by Bristol Myers Squibb - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Thursday, March 11, 2021 - 4:37pm

"Branebrutinib- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's syndrome in 7 Major Markets.

Key Points: 
  • "Branebrutinib- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's syndrome in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Branebrutinib acts as Agammaglobulinaemia tyrosine kinase inhibitors.
  • It is currently in Phase II of clinical trial study for Sjogren's syndrome and is being developed by Bristol Myers Squibb.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Monday, February 22, 2021 - 6:40am

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

Thursday, February 11, 2021 - 9:05pm

A live webcast of the SVB Leerink presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .

Key Points: 
  • A live webcast of the SVB Leerink presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .
  • Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
  • Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies.
  • All statements other than statements of historical facts contained in this press release are forward-looking statements, including, without limitation, Kinnates expected participation at investor conferences.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Wednesday, February 10, 2021 - 1:10am

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Tuesday, February 9, 2021 - 12:10pm

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board

Thursday, February 4, 2021 - 11:30am

SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.

Key Points: 
  • SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.
  • His team identified RSK2 using unbiased functional screens in search of novel drug targets for specific breast cancer subtypes.
  • This research launched Phoenix Molecular Designs in 2012, the only company to have developed a first-in-class small molecule against RSK.
  • Moreover, in the same article that highlighted RSK2 as a target for TNBC, Alan also identified PIK3CA as a target for luminal breast cancer.